Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 64
1952 92
1953 71
1954 47
1955 63
1956 53
1957 54
1958 64
1959 50
1960 49
1961 58
1962 73
1963 68
1964 90
1965 84
1966 92
1967 122
1968 141
1969 220
1970 245
1971 245
1972 234
1973 219
1974 234
1975 227
1976 311
1977 262
1978 273
1979 274
1980 231
1981 268
1982 249
1983 249
1984 264
1985 264
1986 265
1987 264
1988 277
1989 253
1990 291
1991 310
1992 319
1993 334
1994 384
1995 440
1996 554
1997 527
1998 590
1999 637
2000 675
2001 558
2002 513
2003 567
2004 520
2005 589
2006 528
2007 752
2008 673
2009 687
2010 546
2011 548
2012 601
2013 559
2014 695
2015 834
2016 785
2017 970
2018 991
2019 1152
2020 958
2021 752
2022 524
2023 567
2024 231

Text availability

Article attribute

Article type

Publication date

Search Results

26,020 results

Results by year

Filters applied: . Clear all
Page 1
Corrigenda.
[No authors listed] [No authors listed] Br J Dermatol. 2022 Dec 1;187(6):1071-1082. doi: 10.1111/bjd.21884. Br J Dermatol. 2022. PMID: 37578337 No abstract available.
Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trial.
Weidinger S, Bieber T, Cork MJ, Reich A, Wilson R, Quaratino S, Stebegg M, Brennan N, Gilbert S, O'Malley JT, Porter-Brown B. Weidinger S, et al. Br J Dermatol. 2023 Oct 25;189(5):531-539. doi: 10.1093/bjd/ljad240. Br J Dermatol. 2023. PMID: 37463508 Free article. Clinical Trial.
Skin ageing and topical rejuvenation strategies.
Griffiths TW, Watson REB, Langton AK. Griffiths TW, et al. Br J Dermatol. 2023 Oct 30;189(Suppl 1):i17-i23. doi: 10.1093/bjd/ljad282. Br J Dermatol. 2023. PMID: 37903073 Review.
Evaluating bimekizumab safety.
Lovell K, Feldman SR. Lovell K, et al. Br J Dermatol. 2024 Mar 15;190(4):458-459. doi: 10.1093/bjd/ljad451. Br J Dermatol. 2024. PMID: 37979159 No abstract available.
Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse).
Stein Gold LF, Bagel J, Tyring SK, Hong HC, Pavlovsky L, Vender R, Pinter A, Reich A, Drogaris L, Wu T, Patel M, Soliman AM, Photowala H, Stakias V, Richter S, Papp KA. Stein Gold LF, et al. Br J Dermatol. 2023 Oct 25;189(5):540-552. doi: 10.1093/bjd/ljad252. Br J Dermatol. 2023. PMID: 37488811 Clinical Trial.
Efficacy and safety of ciclosporin versus methotrexate in the treatment of severe atopic dermatitis in children and young people (TREAT): a multicentre parallel group assessor-blinded clinical trial.
Flohr C, Rosala-Hallas A, Jones AP, Beattie P, Baron S, Browne F, Brown SJ, Gach JE, Greenblatt D, Hearn R, Hilger E, Esdaile B, Cork MJ, Howard E, Lovgren ML, August S, Ashoor F, Williamson PR, McPherson T, O'Kane D, Ravenscroft J, Shaw L, Sinha MD, Spowart C, Taams LS, Thomas BR, Wan M, Sach TH, Irvine AD; TREAT Trial Investigators. Flohr C, et al. Br J Dermatol. 2023 Nov 16;189(6):674-684. doi: 10.1093/bjd/ljad281. Br J Dermatol. 2023. PMID: 37722926 Free article. Clinical Trial.
26,020 results
You have reached the last available page of results. Please see the User Guide for more information.